Stage III renal cell cancer ajcc V8
Clinical trials for Stage III renal cell cancer ajcc V8 explained in plain language.
Never miss a new study
Get alerted when new Stage III renal cell cancer ajcc V8 trials appear
Sign up with your email to follow new studies for Stage III renal cell cancer ajcc V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Can a smaller dose of this cancer drug still work? new trial aims to find out
Disease control Not yet recruitingThis phase 2 trial is testing whether a lower dose of the immunotherapy drug nivolumab, given less often, can still control cancer in people with various advanced or metastatic cancers. The goal is to see if a cheaper, more accessible regimen works as well as the standard high-co…
Matched conditions: STAGE III RENAL CELL CANCER AJCC V8
Phase 2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Old drug, new hope: mercaptopurine tested against rare cancer syndrome
Disease control Not yet recruitingThis trial tests the drug mercaptopurine in people with hereditary leiomyomatosis and renal cell carcinoma (HLRCC), a rare genetic condition that raises the risk of skin, uterine, and kidney tumors. The study aims to find the safest dose and see if the drug can shrink kidney canc…
Matched conditions: STAGE III RENAL CELL CANCER AJCC V8
Phase 1 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Immunotherapy after kidney surgery may delay cancer return in rare kidney cancer
Disease control Not yet recruitingThis phase III trial compares the immunotherapy drug pembrolizumab to active surveillance (no treatment) after kidney cancer surgery in patients with non-clear cell renal cell carcinoma, a less common type of kidney cancer. The goal is to see if pembrolizumab can help the immune …
Matched conditions: STAGE III RENAL CELL CANCER AJCC V8
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Cold sore virus modified to fight kidney cancer in new trial
Disease control Not yet recruitingThis phase 2 trial tests a combination of RP2 (a modified herpes simplex virus that targets and destroys tumor cells) and tivozanib (a drug that blocks tumor blood vessel growth) in 35 patients with metastatic kidney cancer that worsened after immunotherapy. The goal is to see if…
Matched conditions: STAGE III RENAL CELL CANCER AJCC V8
Phase 2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC